3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Leukemia, Myeloid, Acute
6
Neoplasm Metastasis
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Lung Neoplasms
3
Endometrial Neoplasms
3
Congenital Abnormalities
3
Colonic Neoplasms
3
Breast Neoplasms
3
Sarcoma
2
Oropharyngeal Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Leukemia
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Anus Neoplasms
2
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Interventions
Gemcitabine
73
Fluorouracil
30
Oxaliplatin
20
Leucovorin
20
130-nm albumin-bound paclitaxel
16
Capecitabine
14
Irinotecan
11
Albumin-Bound Paclitaxel
10
irinotecan sucrosofate
8
Radiotherapy
6
Taxes
5
Erlotinib Hydrochloride
5
folfirinox
4
rubitecan
3
Surgical Procedures, Operative
3
Specimen Handling
3
Pancreaticojejunostomy
3
Neoadjuvant Therapy
3
Drug Therapy
3
Cisplatin
3
Chemotherapy, Adjuvant
3
ruxolitinib
2
masitinib
2
dehydroftorafur
2
Saline Solution
2
S 1 (combination)
2
Paclitaxel
2
GV1001 peptide
2
Fentanyl
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pancreatic Neoplasms
×
Observation
×
Clear all
NCT06958328
2026-05-04
LAP100
NRG Oncology
Phase 3
Recruiting
356 enrolled